BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35754234)

  • 1. [Pathological characteristics and clinical prognosis of nodular sclerosis grade 2 of classic Hodgkin's lymphoma].
    Xue XM; Cao Z; Yuan T; Luo YY; Mu JL; Qin Y; Feng XL
    Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):581-586. PubMed ID: 35754234
    [No Abstract]   [Full Text] [Related]  

  • 2. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
    Kelly KM; Hutchinson RJ; Sposto R; Weiner MA; Lones MA; Perkins SL; Massey V;
    Ann Oncol; 2002; 13 Suppl 1():107-11. PubMed ID: 12078889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
    J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
    Niitsu N; Okamoto M; Tomita N; Aoki S; Tamaru J; Miura I; Hirano M
    Leuk Lymphoma; 2006 Sep; 47(9):1908-14. PubMed ID: 17065005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do?
    Connors JM
    Clin Lymphoma; 2005 Jun; 6(1):50-1. PubMed ID: 15989708
    [No Abstract]   [Full Text] [Related]  

  • 7. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
    Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
    Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
    Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of clinical features and treatment outcomes of children with Hodgkin's Lymphoma treated with different chemotherapy protocols at a tertiary care center in Pakistan.
    Mehreen A; Wali RM; Sindhu II; Asad M; Ria S
    J Pak Med Assoc; 2019 Sep; 69(9):1266-1272. PubMed ID: 31511710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
    Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
    Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
    Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating Adults with Hodgkin Lymphoma in the Developing World: a Hospital-Based Cohort Study from Armenia.
    Avagyan A; Danielyan S; Voskanyan A; Sargsyan L; Hakobyan L; Zohrabyan D; Safaryan L; Harutyunyan L; Bardakchyan S; Iskanyan S; Arakelyan S; Tamamyan G
    Asian Pac J Cancer Prev; 2016; 17(1):101-4. PubMed ID: 26838192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hodgkin's lymphoma--the great teacher.
    Connors JM
    N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
    [No Abstract]   [Full Text] [Related]  

  • 18. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
    Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
    Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.